Gabelli & Co Investment Advisers’s The Music Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 TMAC.WS Stock Holding History
Bought
Maintained
Sold
Gabelli & Co Investment Advisers's TMAC.WS Position: Q4 2022 in Review
Gabelli & Co Investment Advisers sold out of The Music Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 (TMAC.WS) in Q4 2022, closing a stake of 37,650 shares — an estimated $2K sold.
Gabelli & Co Investment Advisers first reported a position in TMAC.WS in Q2 2021 and held it in 6 quarters. The position peaked at $32K in Q2 2021. 0 funds tracked by Wall St. Rank hold TMAC.WS as of Q4 2022.
- Gabelli & Co Investment Advisers reported no remaining The Music Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 position as of Q4 2022 after selling out during the quarter.
- Gabelli & Co Investment Advisers sold 37,650 The Music Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 shares in Q4 2022, an estimated $2K.
- Gabelli & Co Investment Advisers first reported a position in The Music Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 in Q2 2021 and held it in 6 quarters.
- Gabelli & Co Investment Advisers's The Music Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 position peaked at $32K in Q2 2021.
- 0 funds tracked by Wall St. Rank held The Music Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 as of Q4 2022.
Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2022, filed 13 Feb 2023.